Jin H. Liu

415 Fengyang Rd
Shanghai, 200003, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

BCMA/CD19 dual-targeting CAR T-cell therapy in older patients with newly diagnosed multiple myeloma: a phase 1 study.

BCMA/CD19 dual-targeting CAR T-cell therapy in older patients with newly diagnosed multiple myeloma: a phase 1 study.

Journal: Blood advances

Published: November 10, 2025

GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial.

GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial.

Journal: The Lancet. Haematology

Published: March 15, 2025

Genomic characteristics and prognostic correlations in Chinese multiple myeloma patients.

Genomic characteristics and prognostic correlations in Chinese multiple myeloma patients.

Journal: BMC medical genomics

Published: October 27, 2024

B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma.

B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma.

Journal: JAMA oncology

Published: July 25, 2024

Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma.

Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma.

Journal: Clinical and experimental immunology

Published: October 04, 2023

Cell-free DNA chromosome copy number variations predict outcomes in plasma cell myeloma.

Cell-free DNA chromosome copy number variations predict outcomes in plasma cell myeloma.

Journal: Blood cancer journal

Published: March 26, 2023

Risk nomogram for assessing renal recovery in patients with newly diagnosed multiple myeloma-related renal impairment.

Risk nomogram for assessing renal recovery in patients with newly diagnosed multiple myeloma-related renal impairment.

Journal: Current problems in cancer

Published: January 18, 2023

The Landscape of Cytogenetic Aberrations in Light-Chain Amyloidosis with or without Coexistent Multiple Myeloma.

The Landscape of Cytogenetic Aberrations in Light-Chain Amyloidosis with or without Coexistent Multiple Myeloma.

Journal: Journal of clinical medicine

Published: January 06, 2023

Sensitive quantitative IgD assay increases progression-free survival prediction accuracy in IgD plasma cell myeloma.

Sensitive quantitative IgD assay increases progression-free survival prediction accuracy in IgD plasma cell myeloma.

Journal: Leukemia

Published: September 13, 2022

Dysregulated circular RNAs are closely linked to multiple myeloma prognosis, with circ_0026652 predicting bortezomib‑based treatment response and survival via the microRNA‑608‑mediated Wnt/β‑catenin pathway.

Dysregulated circular RNAs are closely linked to multiple myeloma prognosis, with circ_0026652 predicting bortezomib‑based treatment response and survival via the microRNA‑608‑mediated Wnt/β‑catenin pathway.

Journal: Oncology reports

Published: January 05, 2021

Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN).

Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN).

Journal: Leukemia

Published: July 03, 2020

Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients.

Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients.

Journal: Annals of hematology

Published: May 26, 2019

Showing 1-12 of 13

Last Updated: 09/26/2026